Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Ana M, Tari"'
Autor:
Naoto T. Ueno, Gabriel N. Hortobagyi, Rene Nieves-Alicea, Tiffany A. LaFortune, Banu K. Arun, Ugur Akar, Ana M. Tari, Dongwei Zhang
Supplementary Figures 1 and 2 from Silencing Kinase-Interacting Stathmin Gene Enhances Erlotinib Sensitivity by Inhibiting Ser10 p27 Phosphorylation in Epidermal Growth Factor Receptor–Expressing Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0472c06566dce5b8c35b970d4efba1da
https://doi.org/10.1158/1535-7163.22485030
https://doi.org/10.1158/1535-7163.22485030
Autor:
Naoto T. Ueno, Gabriel N. Hortobagyi, Rene Nieves-Alicea, Tiffany A. LaFortune, Banu K. Arun, Ugur Akar, Ana M. Tari, Dongwei Zhang
The epidermal growth factor receptor (EGFR) signaling pathway has emerged as a promising target for cancer therapy. EGFR tyrosine kinase inhibitors (TKI) such as erlotinib have been approved for cancer treatment but have shown very limited activity i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03600eeca050b47520ad10b9d1909ebc
https://doi.org/10.1158/1535-7163.c.6531732.v1
https://doi.org/10.1158/1535-7163.c.6531732.v1
Autor:
Ana M. Tari, Gabriel N. Hortobagyi, René Nieves-Alicea, Tiffany A. LaFortune, Dongwei Zhang, Ugur Akar, Naoto T. Ueno, Banu Arun
Publikováno v:
Molecular Cancer Therapeutics. 9:3090-3099
The epidermal growth factor receptor (EGFR) signaling pathway has emerged as a promising target for cancer therapy. EGFR tyrosine kinase inhibitors (TKI) such as erlotinib have been approved for cancer treatment but have shown very limited activity i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f53d638297eea830e759ecca8ef61fba
https://doi.org/10.1158/1535-7163.mct-10-0362
https://doi.org/10.1158/1535-7163.mct-10-0362
Autor:
Vernon E. Steele, Gary J. Kelloff, Ana M. Tari, Marcella M. Johnson, Ann-Marie Simeone, Chu-Xia Deng
Publikováno v:
Carcinogenesis. 26:1000-1007
Women with germline mutations in the breast cancer susceptibility gene BRCA1 are at an increased risk of developing breast cancer. The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been shown to have a clinical chemopreventive activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ddf0a4b6ef4b1055c0e1982d8f92b61
https://doi.org/10.1093/carcin/bgi038
https://doi.org/10.1093/carcin/bgi038
Autor:
Bertrand J. Jean-Claude, Ana M. Tari, Stephanie L. Matheson, Moulay A. Alaoui-Jamali, James P. McNamee, Taiqui Wang
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 311:1163-1170
We have previously reported the synthesis of SMA41, a unimolecular combination of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) of the quinazoline class and a DNA-damaging monomethyltriazene termed “combimolecule”. Hy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37a0ba0f179ca162457d3f9e152a6242
https://doi.org/10.1124/jpet.104.071977
https://doi.org/10.1124/jpet.104.071977
Autor:
Ana M. Tari, Musaffe Tuna, Yu-Jiang Li, Marcella M. Johnson, Ann-Marie Simeone, Lyle D. Broemeling
Publikováno v:
Cancer Research. 64:1224-1228
We reported that HER2/neu reduces the sensitivity of breast cancer cells to N-(4-hydroxyphenyl)retinamide (4-HPR) by suppressing nitric oxide production. We show that HER2/neu uses Akt to induce cyclooxygenase-2 (COX-2) expression and that inhibition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db8a1cffbbf349858a88fc9134377758
https://doi.org/10.1158/0008-5472.can-03-2188
https://doi.org/10.1158/0008-5472.can-03-2188
Publikováno v:
Oncogene. 22:6739-6747
The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR also known as fenretinide) is a potent inducer of apoptosis in breast cancer cells. We observed a 4.5-fold reduction in 4-HPR-mediated apoptosis in MCF-7 breast cancer cells transfected with HER2/neu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46ca167b449cd19cea76b36dfb7e3dfe
https://doi.org/10.1038/sj.onc.1206786
https://doi.org/10.1038/sj.onc.1206786
Autor:
Ana M. Tari, Sangeeta K. Cheema, Rakesh Kumar, Vivek M. Rangnekar, Sandip K. Mishra, Gabriel Lopez-Berestein
Publikováno v:
Journal of Biological Chemistry. 278:19995-20005
Elevated expression levels of the bcl-2 proto-oncogene have been extensively correlated with the appearance of androgen independence in prostate cancer. Although bcl-2 was first cloned as the t(14:18) translocation breakpoint from human follicular B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f6a75dfbea7610b3154a760daff9485
https://doi.org/10.1074/jbc.m205865200
https://doi.org/10.1074/jbc.m205865200
Autor:
Bertrand J. Jean-Claude, James P. McNamee, Fouad Brahimi, Fabienne Dudouit, Ana M. Tari, Stephanie L. Matheson
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 303:238-246
The Combi-Targeting concept postulates that a molecule termed combi-molecule (C-molecule) with binary epidermal growth factor receptor (EGFR) targeting/DNA-damaging properties and with the ability to be hydrolyzed to another EGFR inhibitor should ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::739f6339a3392ea65efc60efd3180ea5
https://doi.org/10.1124/jpet.102.039099
https://doi.org/10.1124/jpet.102.039099
Cyclosporin A enhances the apoptotic effects of N-(4-hydroxyphenyl)retinamide in breast cancer cells
Publikováno v:
International Journal of Cancer. 101:243-247
4HPR, an analogue of ATRA, effectively induces growth inhibition and apoptosis in breast cancer cell lines and animal models but is ineffective against advanced human breast tumors. Different compounds, including tamoxifen, are currently being tested
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5fad1a4b56e8faf3296234f026a36a4
https://doi.org/10.1002/ijc.10596
https://doi.org/10.1002/ijc.10596